{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:09:23Z","timestamp":1784549363675,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijid.2026.108435","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T23:16:24Z","timestamp":1769382984000},"page":"108435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Early administration of neutralizing monoclonal antibodies and post-acute sequelae of COVID-19"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3339-7281","authenticated-orcid":false,"given":"Jinghao Nicholas","family":"Ngiam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang En","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue Tao","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enoch Xueheng","family":"Loy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Chung Yi","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An Ting","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei Xin","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin J.","family":"Chiew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnaby Edward","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Vasoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Chien Boon","family":"Lye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin Bryan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108435_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48502-w","article-title":"Clinical characteristics of Long COVID patients presenting to a dedicated academic post-COVID-19 clinic in Central Texas","volume":"13","author":"Aziz","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2026.108435_bib0002","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1038\/s41598-023-30583-2","article-title":"A prospective cohort study assessing the relationship between long-COVID symptom incidence in COVID-19 patients and COVID-19 vaccination","volume":"13","author":"Abu Hamdh","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2026.108435_bib0003","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41467-020-20501-9","article-title":"Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry","volume":"12","author":"Ge","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2026.108435_bib0004","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108435_bib0005","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108435_bib0006","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/cpt.2700","article-title":"Sotrovimab lowers the risk of COVID-19 related hospitalization or death in a large population cohort in the United Arab Emirates","volume":"112","author":"Saheb Sharif-Askari","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2026.108435_bib0007","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/cid\/ciac855","article-title":"Effectiveness of Evusheld in immunocompromised patients: propensity score\u2013matched analysis","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108435_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102787","article-title":"Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab\/romlusevimab versus placebo in the ACTIV-2 trial","volume":"75","author":"Evering","year":"2024","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.ijid.2026.108435_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069247","article-title":"Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA","volume":"13","author":"Griffin","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijid.2026.108435_bib0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cmi.2022.11.026","article-title":"Increased reporting of venous and arterial thromboembolic events reported with tixagevimab\u2013cilgavimab for coronavirus disease 2019","volume":"29","author":"Montastruc","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2026.108435_bib0011","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2026.108435_bib0012","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/infdis\/jiad014","article-title":"Safety, tolerability and pharmacokinetics of half-life extended severe acute respiratory syndrome coronavirus 2 neutralizing monoclonal antibodies AZD7442 (Tixagevimab-Cilgavimab) in healthy adults","volume":"227","author":"Forte-Soto","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108435_bib0013","unstructured":"US FDA. FDA Announces Evusheld Is Not Currently Authorized for Emergency Use in the U.S., https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us#:\u223c:text=Based%20on%20this%20revision%2C%20Evusheld,SARS%2DCoV%2D2%20variants; 2024 [accessed 11 December 2024]."},{"key":"10.1016\/j.ijid.2026.108435_bib0014","article-title":"Factors associated with delayed diagnosis of symptomatic adult COVID-19 cases presenting to primary care: a population-wide study during transition from Delta to Omicron BA.1 in Singapore","volume":"41","author":"Tan","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.ijid.2026.108435_bib0016","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.cmi.2023.06.016","article-title":"Real-world effectiveness of nirmatrelvir\/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4\/5, and XBB transmission","volume":"29","author":"Wee","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2026.108435_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.30983","article-title":"Autoimmune sequelae after Delta or omicron variant SARS-CoV-2 infection in a highly vaccinated cohort","volume":"7","author":"Wee","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijid.2026.108435_bib0018","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(21)00252-X","article-title":"Singapore\u2019s health-care system: key features, challenges, and shifts","volume":"398","author":"Tan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2026.108435_bib0019","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/cid\/ciad469","article-title":"Long-term cardiovascular, cerebrovascular, and other thrombotic complications in COVID-19 survivors: a retrospective cohort study","volume":"78","author":"Lim","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108435_bib0020","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMsb2408466","article-title":"National Academies of Sciences, Engineering, and Medicine Committee on Examining the Working Definition for Long Covid. Long covid defined","volume":"391","author":"Ely","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108435_bib0022","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2026.108435_bib0023","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1995929","article-title":"The impact of immunogenicity on therapeutic antibody pharmacokinetics: a preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance","volume":"13","author":"Opolka-Hoffmann","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.ijid.2026.108435_bib0024","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.imbio.2012.07.015","article-title":"The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases","volume":"217","author":"Karsten","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.ijid.2026.108435_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102567","article-title":"Mechanistic considerations linking SARS-CoV-2 infection, inflammation, and the loss of immune tolerance","volume":"95","author":"Tonutti","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ijid.2026.108435_bib0026","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1007\/s10067-022-06497-1","article-title":"SARS-CoV-2 infection and SLE: endothelial dysfunction, atherosclerosis, and thrombosis","volume":"42","author":"P\u0142azak","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ijid.2026.108435_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103206","article-title":"COVID-19 and the antiphospholipid syndrome","volume":"21","author":"Serrano","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ijid.2026.108435_bib0028","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood.2021012247","article-title":"Clinical features of thrombosis and bleeding in COVID-19","volume":"140","author":"Thomas","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2026.108435_bib0029","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","article-title":"Association of treatment with nirmatrelvir and the risk of post\u2013COVID-19 condition","volume":"183","author":"Xie","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijid.2026.108435_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074572","article-title":"Molnupiravir and risk of post-acute sequelae of Covid-19: cohort study","volume":"381","author":"Xie","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2026.108435_bib0031","article-title":"Nirmatrelvir\/ritonavir treatment and risk for postacute sequelae of COVID-19 in older Singaporeans","volume":"95","author":"Wee","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2026.108435_bib0032","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1473-3099(22)00129-3","article-title":"Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study","volume":"22","author":"Sheward","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108435_bib0033","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2026.108435_bib0034","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.cmi.2024.04.012","article-title":"An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2","volume":"30","author":"Focosi","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2026.108435_bib0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/14712598.2024.2326647","article-title":"Emerging anti-spike monoclonal antibodies against SARS-CoV-2","volume":"24","author":"Ordaya","year":"2024","journal-title":"Expert Opin Biol Ther"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226000706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226000706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:56:03Z","timestamp":1784548563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226000706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":33,"alternative-id":["S1201971226000706"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108435","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early administration of neutralizing monoclonal antibodies and post-acute sequelae of COVID-19","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108435"}}